Thromboembolic disorders
Adult: 30 u over 5 minutes as a single inj, as soon as possible after onset of symptoms.
Indications and Dosage
Intravenous
Thromboembolic disorders Adult: 30 u over 5 minutes as a single inj, as soon as possible after onset of symptoms.
|
Contraindications
Increased risk of cerebral bleeding including severe hypertension, haemorrhage, recent stroke. Cerebral neoplasm, pregnancy.
|
Special Precautions
Patients with increased risk of bleeding. Active internal bleeding, recent history of peptic ulcer, esophageal varices, ulcerative colitis, other bleeding GI lesions, pancreatitis, subacute bacterial endocarditis, coagulation defects, invasive procedures, mitral stenosis associated with atrial fibrillation. Elderly, diabetic retinopathy.
|
Adverse Reactions
Allergic reactions; fever; nausea and vomiting; haemorrhage; hypotension; pulmonary embolism, acute renal failure, Gullain-Barre syndrome.
Potentially Fatal: Severe internal bleeding. |
Drug Interactions
Increased risk of haemorrhage with heparin, oral anticoagulants, antiplatelet drugs and other drugs that can affect platelet function.
|
Action
Description:
Mechanism of Action: Anistreplase consists of a complex of the lys-form of plasminogen and streptokinase with the addition of a p-anisoyl group that undergoes deacylation upon iv Inj to release the active complex which converts plasminogen to plasmin which has fibrinolytic activity. |